ARIAD, a drug development company working on breakthrough medicines for cancer patients, recently lost an argument in front of the Court of Appeals on a patent infringement case against Eli Lilly.  ARIAD claimed that Eli Lilly was infringing upon their intellectual property in regards to the use of agents that affected the NF-kB pathway.  The case lasted seven years, ultimately resulting in the death of ARIAD’s patent.

How will this affect ARIAD’s prospects for success?  Visit ARIAD’s company profile by clicking in the company profile widget below and leave your own review.